Id: acc3250
Group: 2sens
Protein: CREB
Gene Symbol: CREB1
Protein Id: P16220
Protein Name: CREB1_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Immune system diseases
Disease: Inflammatory
Disease Subtype: Inflammatory Bowel Disease
Disease Cellline: KRJ-I
Disease Info:
Drug: MRS1754
Drug Info: "MRS1754 is a drug that may have specific pharmacological effects and applications, which require further research to fully understand."
Effect: modulate
Effect Info: "Under hypoxic conditions, the ADORA2B receptor activates the MAPK/CREB signaling pathway. TPH - 1 is activated through phosphorylation and synthesizes more 5 - hydroxytryptamine (5 - HT). The ADORA2B agonist NECA can enhance 5 - HT release, while the antagonist MRS1754 can significantly inhibit this process. 5 - HT plays a central role in the regulatory function of EC cells."
Note:
Score: 4.0
Pubmed(PMID): 23638125
Sentence Index:
Sentence:

Sequence & Structure:

MTMESGAENQQSGDAAVTEAENQQMTVQAQPQIATLAQVSMPAAHATSSAPTVTLVQLPNGQTVQVHGVIQAAQPSVIQSPQVQTVQISTIAESEDSQESVDSVTDSQKRREILSRRPSYRKILNDLSSDAPGVPRIEEEKSEEETSAPAITTVTVPTPIYQTSSGQYIAITQGGAIQLANNGTDGVQGLQTLTMTNAAATQPGTTILQYAQTTDGQQILVPSNQVVVQAASGDVQTYQIRTAPTSTIAPGVVMASSPALPTQPAEEAARKREVRLMKNREAARECRRKKKEYVKCLENRVAVLENQNKTLIEELKALKDLYCHKSD

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CREB1-Ser108
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
CREB1-Ser111
Cancer Intensity
BRCA -0.935
COAD 0.719
HGSC
ccRCC -0.651
GBM
HNSC 1.355
LUAD -0.796
LUSC -0.759
non_ccRCC
PDAC
UCEC 1.067
CREB1-Ser142
Cancer Intensity
BRCA 1.677
COAD -0.547
HGSC -0.852
ccRCC -0.202
GBM
HNSC -1.472
LUAD 0.449
LUSC 0.862
non_ccRCC
PDAC
UCEC 0.086
CREB1-Ser143
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CREB1-Ser270
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CREB1-Ser271
Cancer Intensity
BRCA 0.671
COAD 0.307
HGSC -2.002
ccRCC
GBM
HNSC
LUAD 0.269
LUSC
non_ccRCC 0.591
PDAC
UCEC 0.164
CREB1-Ser340
Cancer Intensity
BRCA
COAD 0.347
HGSC 0.586
ccRCC
GBM 1.14
HNSC
LUAD
LUSC -1.245
non_ccRCC
PDAC -0.829
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - P Neuroblastoma Phosphorylation 10366032
- - P Alzheimer's disease Phosphorylation 24523906

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: